Single gene cluster loss may contribute to initiation/progression of multiple myeloma
(American Association for Cancer Research) The loss of one copy of the miR15a/miR16-1 gene cluster promoted initiation and progression of multiple myeloma in mice. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 20, 2020 Category: Cancer & Oncology Source Type: news

Peter Voorhees, MD, Discusses Results from the Ongoing GRIFFIN Study
The study is evaluating daratumumab plus lenalidomide, bortezomib, and dexamethasone in autologous stem cell transplant eligible patients newly diagnosed with multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - February 18, 2020 Category: Cancer & Oncology Authors: Peter Voorhees, MD Source Type: news

Gas Used at Baxter Plant Draws Attention
Gary Beck doesn’t know for certain if his multiple myeloma is linked to his neighbor, a Baxter International plant just blocks away in Mountain Home. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - February 17, 2020 Category: American Health Source Type: news

Andrew J. Cowan, MD, Discusses the Phase I Clinical Trial of GSI and BCMA CAR T-Cells
The expert explained the rationale for the phase I first-in-human clinical trial evaluating the combination of a gamma-secretase inhibitor and B-cell maturation antigen CAR T-cells in patients with heavily pretreated multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - February 17, 2020 Category: Cancer & Oncology Authors: Andrew J. Cowan, MD Source Type: news

Nina Shah, MD, on the Safety and Efficacy of CAR T-Cell Therapies for Multiple Myeloma
The associate professor of clinical medicine discussed the main side effects of CAR T-cell therapies when treating multiple myeloma, and how to combat them. (Source: CancerNetwork)
Source: CancerNetwork - February 15, 2020 Category: Cancer & Oncology Authors: Nina Shah, MD Source Type: news

State of the Science for Multiple Myeloma: Change in the Right Direction
In a workshop conducted by the FDA and AACR, researchers from various institutions discussed the current state of African American outcomes and treatment in multiple myeloma trials and the clinical implications. (Source: CancerNetwork)
Source: CancerNetwork - February 14, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Recommendations for Under-Representation of African Americans in Multiple Myeloma
In a workshop conducted by the FDA and the AACR, working groups came together to address disparities in the representation of African Americans in multiple myeloma clinical trials and to create a set of recommendations in an attempt resolve them. (Source: CancerNetwork)
Source: CancerNetwork - February 14, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Janssen Submits sBLA for Daratumumab Combo to Treat Multiple Myeloma
Janssen Pharmaceutical Companies submitted a supplemental biologics license application for daratumumab in combination with carfilzomib and dexamethasone to treat patients with relapsed/refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - February 11, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Janssen Announces Submission to U.S. FDA for New DARZALEX ® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “W...
Source: Johnson and Johnson - February 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

New CAR-T target yields promising results for multiple myeloma
(Huntsman Cancer Institute) In research published today in the journal Nature Communications, Utah-based scientists describe a novel way to treat cancers using chimeric antigen receptor (CAR) T cell therapy. Laboratory tests using mouse models and tumor cells from patients displayed promising results for this novel cellular immunotherapy for multiple myeloma and other types of blood cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 7, 2020 Category: Cancer & Oncology Source Type: news

Reirradiation Rarely Required in Focal RT for Multiple Myeloma
FRIDAY, Jan. 31, 2020 -- For patients with multiple myeloma receiving focal radiation therapy (RT) for symptomatic plasmacytoma, reirradiation is rarely required, according to a letter to the editor published online Jan. 9 in Haematologica. Adnan... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 31, 2020 Category: Pharmaceuticals Source Type: news

Georgia Sterilization Plant Hit with Hefty Fines for EtO Violation
An Atlanta, GA-based medical sterilization plant is learning an expensive lesson after missing a critical deadline related to ethylene oxide (EtO) pollution controls. Sterilization Services of Georgia received a permit on Nov. 7 to use EtO to sterilize medical devices, but the company was supposed to install filters to reduce the gas by Dec. 31. The filters were fully operational as of Jan. 18, according to a Jan. 20 letter, but the Georgia Environmental Protection Department (EPD) fined the company $3,000 for each day beyond the deadline that the filters were not connected. In the letter to the Geo...
Source: MDDI - January 30, 2020 Category: Medical Devices Authors: Amanda Pedersen Tags: Sterilization Source Type: news

FDA Grants Priority Review of Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma
Issued: London, UK -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) granted a priority review for the company’s Biologics License Application (BLA) seeking approval of belantamab mafodotin (GSK2857916)... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - January 27, 2020 Category: Drugs & Pharmacology Source Type: news

Drug Trials Snapshots: XPOVIO
XPOVIO is a drug used to treat a form of blood cancer called multiple myeloma. It is to be used in combination with dexamethasone (a type of corticosteroid) in patients with no other treatment options whose cancer came back after, or did not respond to, at least four previous treatments. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 27, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA-AACR Workshop to Examine Under-representation of African Americans in Multiple Myeloma Clinical Trials - 02/13/2020 - 02/13/2020
FDA-AACR Workshop to Examine Under-representation of African Americans in Multiple Myeloma Clinical Trials (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 23, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Grants Priority Review to Belantamab Mafodotin for Relapsed/Refractory Myeloma
The agency granted the immunoconjugate targeting B-cell maturation antigen priority review to belantamab mafodotin for the treatment of heavily pre-treated patients with relapsed or refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - January 21, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Sept. 11 Responders May Be at Heightened Risk of Developing Leukemia
After the Twin Towers fell on Sept. 11, 2001, the thousands of people involved in rescue-and-cleanup efforts were exposed to carcinogens and other toxins as they breathed in contaminated air and dug through industrial rubble. Studies completed since then have shown elevated rates of conditions including multiple myeloma, prostate cancer and thyroid cancer among 9/11 responders and those who worked near the site. A new study published Jan. 14 in the journal JNCI Cancer Spectrum adds another to that list: leukemia. “After about 12 years of follow-up, there was an increase in the rate of all cancers combined, and separa...
Source: TIME: Health - January 14, 2020 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Cancer Research Source Type: news

The Big Number: Why your risks for 7 types of cancer could be reduced with physical activity
Research shows several exercises can be effective against these cancers: breast, colon, endometrial, kidney, liver, multiple myeloma and non-Hodgkin lymphoma. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - January 12, 2020 Category: Consumer Health News Authors: Linda Searing Source Type: news

Former Celgene Chairman and CEO Mark J. Alles Joins Antengene Board of Directors
SHANGHAI and PHILADELPHIA, Jan. 8, 2020 -- (Healthcare Sales & Marketing Network) -- The Antengene board today announced the appointment of Mr. Mark J. Alles as an independent director of the company, effective January 2, 2020. Mr. Alles is the former Cha... Biopharmaceuticals, Oncology, Personnel Antengene, selinexor, multiple myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 8, 2020 Category: Pharmaceuticals Source Type: news

Top Stories in Multiple Myeloma From ASH 2019 Top Stories in Multiple Myeloma From ASH 2019
Dr Joseph Mikhael highlights data on front-line therapy in multiple myeloma that indicate benefit from the addition of daratumumab to standard induction combinations, as presented at ASH 2019.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 2, 2020 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news

Frailty Score May Predict Outcomes in Multiple Myeloma
Frailty score based on age, Charlson Comorbidity Index, ECOS PS predicts outcomes in FIRST trial (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 1, 2020 Category: Cancer & Oncology Tags: Oncology, Geriatrics, Journal, Source Type: news

Frailty Score May Predict Outcomes in Multiple Myeloma
TUESDAY, Dec. 31, 2019 -- A frailty scale that includes Eastern Cooperative Oncology Group performance status (ECOG PS) may predict outcomes for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM), according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 31, 2019 Category: Pharmaceuticals Source Type: news

Exercise may reduce risk for cancer by as much as 25 percent
People who engaged in physical activity as recommended by the NIH were able to reduce their risk for colon and breast cancers, as well as endometrial cancer, kidney cancer, myeloma, liver cancer and non-Hodgkin lymphoma. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 26, 2019 Category: Consumer Health News Source Type: news

Belantamab Mafodotin Elicits Responses in R/R Multiple Myeloma Belantamab Mafodotin Elicits Responses in R/R Multiple Myeloma
A novel agent that targets B-cell maturation antigen achieved overall responses in more than 30% of heavily pretreated relapsed/refractory multiple myeloma patients; the drug is awaiting approval.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 23, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Researchers identify potential formula for blood cancer vaccine
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way to move precision immunotherapy forward by using genomics to inform immunotherapy for multiple myeloma, a blood cancer, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research, in December. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 19, 2019 Category: Cancer & Oncology Source Type: news

Denosumab Increasingly Used in Myeloma Despite High Cost Denosumab Increasingly Used in Myeloma Despite High Cost
Denosumab has captured 40% of the market share in just over a year despite a lack of superiority with zoledronic acid and a much higher price tag.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 18, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Britain's GSK seeks U.S approval for rival to J & J's multiple myeloma drug
GlaxoSmithKline said on Monday it had applied for U.S. approval for its experimental multiple myeloma drug that showed meaningful response in nearly a third of patients, setting up a battle against Johnson& Johnson and Genmab's Darzalex. (Source: Reuters: Health)
Source: Reuters: Health - December 17, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Quiz: Managing Relapsed/Refractory Multiple Myeloma
In our multiple myeloma quiz, you'll get a chance to test your knowledge on best practices to treating patients with relapsed/refractory multiple myeloma (Source: CancerNetwork)
Source: CancerNetwork - December 16, 2019 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news

BCMA-targeted immunotherapy can lead to durable responses in multiple myeloma
(University of Pennsylvania School of Medicine) An experimental, off-the-shelf immunotherapy that combines a targeted antibody and chemotherapy can lead to potentially durable responses in multiple myeloma patients whose disease has relapsed or is resistant to other standard therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 16, 2019 Category: Cancer & Oncology Source Type: news

DARZALEX ® (Daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma
· First Phase 3 study showing addition of the CD38-directed antibody DARZALEX® to carfilzomib in combination with dexamethasone· Data selected as a Late-Breaking Abstract at ASH 2019 (Source: Johnson and Johnson)
Source: Johnson and Johnson - December 10, 2019 Category: Pharmaceuticals Source Type: news

New Triplet, New Standard of Care in Relapsed Myeloma? New Triplet, New Standard of Care in Relapsed Myeloma?
A new triplet regimen -- carfilzomib, dexamethasone, and daratumumab -- has shown good results in patients with relapsed or refractory multiple myeloma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 10, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at the 2019 ASH Annual Meeting
SUZHOU, China, Dec. 10, 2019 -- (Healthcare Sales & Marketing Network) -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of o... Biopharmaceuticals, Oncology Innovent Biologics, IASO Biotherapeutics, BCMA CAR-T, Cell Therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 10, 2019 Category: Pharmaceuticals Source Type: news

Bluebird bio, Bristol-Myers' multiple myeloma therapy shows promise in early study
Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments. (Source: Reuters: Health)
Source: Reuters: Health - December 10, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

DARZALEX ® (Daratumumab) Shows Overall Survival Benefit and Continued Improvement in Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant
· Updated data from the Phase 3 ALCYONE study showed an overall survival benefit and continued improvement in progression-free survival after a median duration of follow-up of more than three years with DARZALEX®; results simultaneously published in The Lancet· DARZALEX® is the only CD38-directe d antibody to show an overall survival benefit in multiple myeloma· Additionally, follow-up data from the Phase 3 MAIA study showed significant progression-free survival benefit continuing for three years following DARZALEX® treatment (Source: Johnson and Johnson)
Source: Johnson and Johnson - December 9, 2019 Category: Pharmaceuticals Source Type: news

Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma
Results from Phase 1b/2 CARTITUDE-1 to premiere in oral presentation at ASH 2019 (Abstract #577) (Source: Johnson and Johnson)
Source: Johnson and Johnson - December 9, 2019 Category: Pharmaceuticals Source Type: news

Janssen Announces BCMA CAR-T Therapy JNJ-4528 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Relapsed or Refractory Multiple Myeloma
Newest designation for JNJ-4528 is supported by Phase 1b/2 CARTITUDE-1 study in adults with relapsed or refractory multiple myelomaInitial results from CARTITUDE-1 study to premiere at the American Society of Hematology Annual Meeting (Source: Johnson and Johnson)
Source: Johnson and Johnson - December 9, 2019 Category: Pharmaceuticals Source Type: news

Dana-Farber scientists present promising findings in multiple myeloma at ASH Annual Meeting
(Dana-Farber Cancer Institute) Results of studies on a novel agent to treat multiple myeloma and a combination therapy aimed at slowing the progression of a precursor myeloma condition are among reports being presented by Dana-Farber Cancer Institute investigators at the ASH Annual Meeting. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 9, 2019 Category: Cancer & Oncology Source Type: news

Increase in Autologous HSCT for Myeloma, Decline in Allogeneic Increase in Autologous HSCT for Myeloma, Decline in Allogeneic
Autologous hematopoietic stem cell transplants have increased globally, but predominantly in high income nations, and there are marked disparities in usage.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 9, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Myeloma Patients Over Age 70 Can Benefit From Auto-HC Transplant Myeloma Patients Over Age 70 Can Benefit From Auto-HC Transplant
"Age has no implication in terms of the antimyeloma effect of transplant," said one oncologist. Researchers called this largest study of auto-HCT in older adults with multiple myeloma.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - December 8, 2019 Category: Surgery Tags: Hematology-Oncology News Source Type: news

CAR T-Cell Therapy on the Horizon for R/R Multiple Myeloma CAR T-Cell Therapy on the Horizon for R/R Multiple Myeloma
Two products have shown impressive responses, and CAR T-cell therapy may soon find its way into the treatment landscape of relapsed or refractory multiple myeloma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 7, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Extramedullary Multiple Myeloma Responds to Dual-Targeting CAR T-Cell Therapy
Chimeric antigen receptor T-cell therapy targeting both BCMA and CD38 induced an objective response in>90% of patients with multiple myeloma who had been treated with at least 3 prior therapies and whose disease had spread outside of the bone marrow. (Source: CancerNetwork)
Source: CancerNetwork - December 7, 2019 Category: Cancer & Oncology Authors: Audrey Sternberg Source Type: news

Anti-BCMA, CD3 Agent CC-93269 Shows Promise for Heavily Pretreated Myeloma
CC-93269 showed encouraging signs of dose-dependent efficacy with a safety profile that continues to be refined for patients with heavily pretreated relapsed/refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - December 7, 2019 Category: Cancer & Oncology Authors: Silas Inman Source Type: news

Promising Responses from Dual-Targeting CAR T-Cell Therapy in Myeloma Support Further Exploration
Chimeric antigen receptor T-cell therapy targeting both BCMA and CD38 induced an objective response in>90% of patients with multiple myeloma who had been treated with at least 3 prior therapies and whose disease had spread outside of the bone marrow. (Source: CancerNetwork)
Source: CancerNetwork - December 7, 2019 Category: Cancer & Oncology Authors: Audrey Sternberg Source Type: news

CC-93269 Demonstrates Promising Dose-Dependent Efficacy in Heavily Pretreated Myeloma
CC-93269 showed encouraging signs of dose-dependent efficacy with a safety profile that continues to be refined for patients with heavily pretreated relapsed/refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - December 7, 2019 Category: Cancer & Oncology Authors: Silas Inman Source Type: news

Bristol-Myers, bluebird therapy for multiple myeloma succeeds in mid-stage trial
Bristol-Myers Squibb Co and bluebird bio Inc said on Friday their experimental therapy for a type of multiple myeloma met the main goal in a mid-stage study. (Source: Reuters: Health)
Source: Reuters: Health - December 6, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Addressing the Challenges of Treatment Sequencing in Multiple Myeloma
Sham Mailankody, MBBS, discussed the challenge of determining an optimal sequence of treatments in patients with relapsed/refractory multiple myeloma, and how head-to-head studies can help. (Source: CancerNetwork)
Source: CancerNetwork - December 3, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Oncopeptides Appoints Joseph Horvat as President North America
STOCKHOLM, Dec. 2, 2019 -- (Healthcare Sales & Marketing Network) -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Joseph Horvat has been appointed as President North America and CEO of Oncopetides Inc. Joseph will serve on the Management ... Biopharmaceuticals, Oncology, Personnel Oncopeptides, melflufen, Multiple Myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 2, 2019 Category: Pharmaceuticals Source Type: news

Featured Review: Reducing uncertainties in choosing first-line treatment in newly diagnosed multiple myeloma
Multiple myeloma is a type of blood cancer. It accounts for approximately 2% of all cancers and is still considered incurable. For people with newly diagnosed multiple myeloma (NDMM), who are unsuitable for a procedure where damaged blood cells are replaced with healthy ones (stem-cell transplant), treatment is usually a multiple drug combination of bortezomib, lenalidomide, or thalidomide, plus melphalan and prednisolone (MP) or dexamethasone (D). Multiple drug combinations are approved for initial anti-myeloma therapy, however, access to these medicines is restricted in many countries worldwide.The Cochrane Review used n...
Source: Cochrane News and Events - November 26, 2019 Category: Information Technology Authors: Katie Abbotts Source Type: news

FDA Takes Action to Reduce EtO Use
Shutdowns earlier this year of two facilities that use ethylene oxide (EtO) to sterilize medical devices prompted FDA to monitor for supply shortages in the industry because EtO is such a popular sterilization method for medical devices. This week the agency revealed steps it will take to reduce medtech's reliance on EtO sterilization. EtO is a flammable, colorless gas used to sterilize equipment and plastic devices that cannot be sterilized by steam, such as medical equipment. In fact, about half of all sterilized medical devices undergo sterilization using this gas. Breathi...
Source: MDDI - November 25, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Sterilization Regulatory and Compliance Source Type: news

Lenalidomide Slows Progression of Smoldering Multiple Myeloma Lenalidomide Slows Progression of Smoldering Multiple Myeloma
Early treatment with lenalidomide significantly delays the progression of smoldering multiple myeloma to symptomatic disease, according to the results of a randomized trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 23, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news